Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 21, 2004

View Archived Issues

Direct antiplatelet effects of the novel engineered human apyrase APT-102

Preclinical characterization of the orally active factor Xa inhibitor, DU-176b

Preclinical effects of the novel thrombopoietin receptor agonist, SB-559457, on hematopoietic cells

Acusphere enrolls 300 in pivotal program for AI-700

Alcon completes NDA filing for Retaane

Avanir commences NDA submission for Neurodex

Updates on Xyotax pivotal studies

No overall survival benefit with Iressa in ISEL study

Clevelox ESCAPE-1 study meets objectives

Positive data from ongoing studies of rhC1INH for hereditary angioedema

Exelixis plans phase I study of XL-880 for 2005

Abbott seeks U.S., European approvals of Humira for psoriatic arthritis

Allos Therapeutics acquires license to chemotherapeutic agent RH1

CXCR inhibition as a therapeutic strategy in leukemia

Potential neuroprotective effects for rifampicin in Parkinson's disease

Fast track designation for Remicade for ulcerative colitis

Scientists at Pfizer describe a novel series of PDE9 inhibitors

Abbott discloses MCH receptor antagonists in a recent patent

Compounds for the treatment of ischemic diseases described in patent literature

Sankyo patent claims chromane analogues and their use in diabetes, hyperlipidemia, etc.

A new series of beta3 receptor agonists in early development at Dainippon

Kyowa Hakko isolates antiinflammatory compound from a natural source

SB-715992 enters new phase II study for advanced ovarian cancer

INS-50589 Cardiovascular tested in new phase I study

Perifosine shows promise in the treatment of metastatic breast cancer

667-Coumate enters phase I development for breast cancer

Therapeutic benefits reported for modafinil in cocaine dependence and MDD

Cardiovascular risks halt use of celecoxib in study/News in Context

Lundbeck files for E.U. approval of Cipralex for generalized anxiety disorder

Avastin approved in Switzerland

New Invirase 500 mg receives FDA approval

Macugen approved for neovascular AMD

Myozyme MAA accepted in Europe for Pompe disease

TAK-559 placed on hold

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...